Smoking-associated Downregulation of FILIP1L Enhances Lung Adenocarcinoma Progression Through Mucin Production, Inflammation, and Fibrosis.


Journal

Cancer research communications
ISSN: 2767-9764
Titre abrégé: Cancer Res Commun
Pays: United States
ID NLM: 9918281580506676

Informations de publication

Date de publication:
10 2022
Historique:
received: 09 06 2022
revised: 19 07 2022
accepted: 07 09 2022
entrez: 2 3 2023
pubmed: 3 3 2023
medline: 3 3 2023
Statut: epublish

Résumé

Lung adenocarcinoma (LUAD) is the major subtype in lung cancer, and cigarette smoking is essentially linked to its pathogenesis. We show that downregulation of Filamin A interacting protein 1-like (FILIP1L) is a driver of LUAD progression. Cigarette smoking causes its downregulation by promoter methylation in LUAD. Loss of FILIP1L increases xenograft growth, and, in lung-specific knockout mice, induces lung adenoma formation and mucin secretion. In syngeneic allograft tumors, reduction of FILIP1L and subsequent increase in its binding partner, prefoldin 1 (PFDN1) increases mucin secretion, proliferation, inflammation, and fibrosis. Importantly, from the RNA-sequencing analysis of these tumors, reduction of FILIP1L is associated with upregulated Wnt/β-catenin signaling, which has been implicated in proliferation of cancer cells as well as inflammation and fibrosis within the tumor microenvironment. Overall, these findings suggest that down-regulation of FILIP1L is clinically relevant in LUAD, and warrant further efforts to evaluate pharmacologic regimens that either directly or indirectly restore FILIP1L-mediated gene regulation for the treatment of these neoplasms. This study identifies FILIP1L as a tumor suppressor in LUADs and demonstrates that downregulation of FILIP1L is a clinically relevant event in the pathogenesis and clinical course of these neoplasms.

Identifiants

pubmed: 36860703
doi: 10.1158/2767-9764.CRC-22-0233
pii: CRC-22-0233
pmc: PMC9973389
doi:

Substances chimiques

Mucins 0
FILIP1L protein, human 0
Intracellular Signaling Peptides and Proteins 0

Types de publication

Journal Article Research Support, N.I.H., Extramural

Langues

eng

Pagination

1197-1213

Subventions

Organisme : NCI NIH HHS
ID : P30 CA072720
Pays : United States

Informations de copyright

© 2022 The Authors; Published by the American Association for Cancer Research.

Références

Cancer Sci. 2018 Jun;109(6):2063-2073
pubmed: 29701925
Oncogene. 2018 Aug;37(33):4518-4533
pubmed: 29743597
J Thorac Oncol. 2015 Jan;10(1):19-27
pubmed: 25319180
Mol Cancer Res. 2011 Aug;9(8):1126-38
pubmed: 21693594
Oncogene. 2019 Sep;38(36):6354-6369
pubmed: 31320708
Nat Commun. 2017 Feb 01;8:14381
pubmed: 28146145
Nat Commun. 2018 Dec 18;9(1):5363
pubmed: 30560893
BMC Cancer. 2021 Jan 23;21(1):96
pubmed: 33485313
JTO Clin Res Rep. 2021 May 08;2(7):100181
pubmed: 34790904
Oncotarget. 2014 Jun 15;5(11):3636-50
pubmed: 25004243
J Biol Chem. 2002 Oct 11;277(41):38239-44
pubmed: 12154096
Cancer Discov. 2014 Apr;4(4):415-22
pubmed: 24469108
Carcinogenesis. 2021 Dec 31;42(12):1461-1474
pubmed: 34487521
BMC Cancer. 2019 Aug 20;19(1):824
pubmed: 31429720
Cancer Metastasis Rev. 2019 Jun;38(1-2):223-236
pubmed: 30618016
Front Oncol. 2018 Jun 04;8:195
pubmed: 29915721
Immunol Res. 2007;38(1-3):112-21
pubmed: 17917016
Mol Oncol. 2016 Feb;10(2):224-39
pubmed: 26526617
J Natl Cancer Inst. 2013 Dec 18;105(24):1871-80
pubmed: 24249745
Int J Cancer. 2014 Jul 1;135(1):48-60
pubmed: 24327474
MethodsX. 2019 Oct 18;6:2468-2475
pubmed: 31720237
Cancer Res. 2008 Sep 15;68(18):7332-41
pubmed: 18794120
J Cell Mol Med. 2020 Jun;24(12):6804-6821
pubmed: 32352211
Clin Epigenetics. 2021 Jun 9;13(1):126
pubmed: 34108011
Front Cell Dev Biol. 2022 Jan 17;9:816214
pubmed: 35111762
Int J Mol Med. 2018 Aug;42(2):713-725
pubmed: 29786110
Semin Cell Dev Biol. 2017 Apr;64:73-78
pubmed: 27569189
CA Cancer J Clin. 2022 Jan;72(1):7-33
pubmed: 35020204
Antioxid Redox Signal. 2019 Mar 10;30(8):1124-1143
pubmed: 29634348
Nature. 2017 May 18;545(7654):355-359
pubmed: 28489818
J Immunol. 2004 Apr 1;172(7):4510-9
pubmed: 15034068
Dev Cell. 2014 Dec 8;31(5):525-38
pubmed: 25490264
Cancer Res. 2021 Nov 1;81(21):5523-5539
pubmed: 34417201
Front Immunol. 2018 Mar 20;9:563
pubmed: 29662489
Nat Med. 2015 Aug;21(8):938-945
pubmed: 26193342
Pediatr Res. 2021 Apr;89(5):1126-1135
pubmed: 32303051
J Innate Immun. 2017;9(3):281-299
pubmed: 28052300
J Pathol. 2014 May;233(1):7-17
pubmed: 24258247
Sci Rep. 2015 Mar 03;5:8649
pubmed: 25733373
Science. 2016 Nov 4;354(6312):618-622
pubmed: 27811275
Proc Natl Acad Sci U S A. 2013 Aug 27;110(35):14219-24
pubmed: 23940311
Cancer Cell. 2017 Sep 11;32(3):360-376.e6
pubmed: 28898697
Onco Targets Ther. 2020 Apr 16;13:3177-3186
pubmed: 32368077
EBioMedicine. 2021 May;67:103383
pubmed: 34000624
J Thorac Dis. 2017 Oct;9(10):4017-4026
pubmed: 29268412
CA Cancer J Clin. 2018 Jan;68(1):31-54
pubmed: 29160902
Nat Protoc. 2009;4(7):1064-72
pubmed: 19561589
Biosci Rep. 2020 Feb 28;40(2):
pubmed: 31957800
J Urol. 2013 Jan;189(1):329-35
pubmed: 23174249
J Cell Biol. 2005 Feb 14;168(4):633-42
pubmed: 15716380
J Leukoc Biol. 2013 Oct;94(4):585-94
pubmed: 23543767
JCI Insight. 2019 Dec 19;4(24):
pubmed: 31852841
Cancer Epidemiol Biomarkers Prev. 2014 Sep;23(9):1729-51
pubmed: 24962838
Int J Cancer. 1996 Dec 20;69(6):457-65
pubmed: 8980247
Genome Res. 2012 Jul;22(7):1197-211
pubmed: 22613842
Cancer Res. 2001 Aug 15;61(16):6050-4
pubmed: 11507052
Chest. 2018 Jul;154(1):169-176
pubmed: 29170036
Cancers (Basel). 2020 Apr 24;12(4):
pubmed: 32344577
Oncotarget. 2016 Nov 1;7(44):72229-72241
pubmed: 27750216
Cell. 2019 Jul 11;178(2):330-345.e22
pubmed: 31257027
PLoS One. 2013 Dec 05;8(12):e82620
pubmed: 24340050
Cell. 2002 Mar 22;108(6):837-47
pubmed: 11955436
Nature. 2020 Feb;578(7794):266-272
pubmed: 31996850
Cancer Res. 2006 Jul 15;66(14):7024-31
pubmed: 16849547
EMBO Mol Med. 2017 Apr;9(4):462-481
pubmed: 28255028
Oncogene. 1996 Feb 1;12(3):555-62
pubmed: 8637712
Genes Dev. 2004 Nov 15;18(22):2718-23
pubmed: 15545629
Clin Lung Cancer. 2017 Jul;18(4):e273-e281
pubmed: 28065467
Front Immunol. 2018 Nov 19;9:2625
pubmed: 30510554
Mol Aspects Med. 2020 Dec;76:100859
pubmed: 32386845
J Clin Invest. 2013 Mar;123(3):1241-61
pubmed: 23426183
J Clin Med. 2019 Sep 11;8(9):
pubmed: 31514468
Gastroenterology. 2005 Jul;129(1):285-302
pubmed: 16012954
Cancers (Basel). 2018 Jul 27;10(8):
pubmed: 30060526
Nat Immunol. 2007 Sep;8(9):931-41
pubmed: 17694059
Oncogene. 2010 Apr 1;29(13):1929-40
pubmed: 20062083
Curr Genomics. 2021 Feb;22(2):79-87
pubmed: 34220295
Cancers (Basel). 2022 Feb 15;14(4):
pubmed: 35205708
Front Oncol. 2020 Sep 11;10:1766
pubmed: 33014869
J Clin Invest. 2012 Dec;122(12):4388-400
pubmed: 23143308
Oncotarget. 2016 Nov 22;7(47):77052-77070
pubmed: 27776341
Med Oncol. 2015 Dec;32(12):264
pubmed: 26553318
Carcinogenesis. 2019 Apr 29;40(2):324-334
pubmed: 30698677
Nat Commun. 2017 Dec 21;8(1):2238
pubmed: 29269828
Life Sci. 2021 Dec 1;286:120061
pubmed: 34666037
Ann Transl Med. 2020 May;8(10):651
pubmed: 32566588
Oncogene. 2017 Feb 16;36(7):885-898
pubmed: 27694898
Sci Rep. 2021 Dec 2;11(1):23337
pubmed: 34857857
Am J Physiol Lung Cell Mol Physiol. 2017 Mar 1;312(3):L334-L347
pubmed: 28011616
Int J Mol Sci. 2019 Jan 30;20(3):
pubmed: 30704051
Am J Pathol. 1999 Oct;155(4):1033-8
pubmed: 10514384
PLoS One. 2019 Nov 25;14(11):e0225755
pubmed: 31765425
Oncogene. 2010 Jun 24;29(25):3650-64
pubmed: 20440268
Genome Biol. 2006;7(10):R100
pubmed: 17076895

Auteurs

Mijung Kwon (M)

Rutgers Cancer Institute of New Jersey, New Brunswick, New Jersey.

Genesaret Rubio (G)

Rutgers Cancer Institute of New Jersey, New Brunswick, New Jersey.

Haitao Wang (H)

Thoracic Surgery Branch, Center for Cancer Research, NCI, Bethesda, Maryland.

Gregory Riedlinger (G)

Department of Pathology, Robert Wood Johnson Medical School, Rutgers University, New Brunswick, New Jersey.

Asha Adem (A)

Rutgers Cancer Institute of New Jersey, New Brunswick, New Jersey.

Hua Zhong (H)

Rutgers Cancer Institute of New Jersey, New Brunswick, New Jersey.

Daniel Slegowski (D)

Rutgers Cancer Institute of New Jersey, New Brunswick, New Jersey.

Louisa Post-Zwicker (L)

Rutgers Cancer Institute of New Jersey, New Brunswick, New Jersey.

Anshruta Chidananda (A)

Rutgers Cancer Institute of New Jersey, New Brunswick, New Jersey.

David S Schrump (DS)

Thoracic Surgery Branch, Center for Cancer Research, NCI, Bethesda, Maryland.

Sharon R Pine (SR)

Rutgers Cancer Institute of New Jersey, New Brunswick, New Jersey.
Departments of Pharmacology and Medicine, Robert Wood Johnson Medical School, Rutgers University, New Brunswick, New Jersey.

Steven K Libutti (SK)

Rutgers Cancer Institute of New Jersey, New Brunswick, New Jersey.

Articles similaires

[Redispensing of expensive oral anticancer medicines: a practical application].

Lisanne N van Merendonk, Kübra Akgöl, Bastiaan Nuijen
1.00
Humans Antineoplastic Agents Administration, Oral Drug Costs Counterfeit Drugs

Smoking Cessation and Incident Cardiovascular Disease.

Jun Hwan Cho, Seung Yong Shin, Hoseob Kim et al.
1.00
Humans Male Smoking Cessation Cardiovascular Diseases Female
Humans United States Aged Cross-Sectional Studies Medicare Part C
1.00
Humans Yoga Low Back Pain Female Male

Classifications MeSH